Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant

Angie Szumlinski Announcements

Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. More information can be found at the link below: